International Journal of Molecular Sciences · 2022 · 32 citations · 39 references
MedicineCardiologyPharmacologyMitochondrial BiologyMolecular PharmacologyPharmacodynamicsCardiac PharmacotherapyCardiovascular PathophysiologyCardiovascular PharmacologyDiabetes PharmacotherapyMitochondrial DysfunctionMitochondrial PhysiologyCardiac Mitochondrial FunctionCardioprotective TherapyDiabetic CardiomyopathyInflammatory Cardiac BiomarkersMitochondrial Function In CardiomyocytesMitochondrial Respiration ControlMitochondrial Respiration InhibitionPyroptosis Mechanisms
There is a new form of puerarin, puerarin-V, that has recently been developed, and it is unclear whether puerarin-V has a cardioprotective effect on diabetic cardiomyopathy (DCM). Here, we determined whether puerarin-V had any beneficial influence on the pathophysiology of DCM and explored its possible mechanisms. By injecting 30 mg/kg of STZ intraperitoneally, diabetes was induced in rats. After a week of stability, the rats were injected subcutaneously with ISO (5 mg/kg). We randomly assigned the rats to eight groups: (1) control; (2) model; (3) metformin; (4-6) puerarin-V at different doses; (7) puerarin (API); (8) puerarin injection. DCM rats were found to have severe cardiac insufficiency (arrythmia, decreased LVdP/dt, and increased E/A ratio). In addition, cardiac injury biomarkers (cTn-T, NT-proBNP, AST, LDH, and CK-MB), inflammatory cytokines (IL-1β, IL-18, IL-6, and TNF-α), and oxidative damage markers (MDA, SOD and GSH) were markedly increased. Treatment with puerarin-V positively adjusts these parameters mentioned above by improving cardiac function and mitochondrial respiration, suppressing myocardial inflammation, and maintaining the structural integrity of the cardiac muscle. Moreover, treatment with puerarin-V inhibits the P2X7 receptor-mediated pyroptosis pathway that was upregulated in diabetic hearts. Given these results, the current study lends credence to the idea that puerarin-V can reduce myocardial damage in DCM rats. Furthermore, it was found that the effect of puerarin-V in diabetic cardiomyopathy is better than the API, the puerarin injection, and metformin. Collectively, our research provides a new therapeutic option for the treatment of DCM in clinic.
39
Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death
Peter J. Mohler, Jean‐Jacques Schott, Anthony O. Gramolini et al. · Nature · 2003 · 960 citations
Medicine, Cardiology, Genetics +15
Streptozotocin‐Induced Diabetic Models in Mice and Rats
Brian L. Furman · Current Protocols · 2021 · 826 citations · Full text